James E Crowe Selected Research

Ebola Vaccines

1/2021	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
1/2019	Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
1/2019	Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James E Crowe Research Topics

Disease

98	Infections 10/2022 - 04/2003
31	Human Influenza (Influenza) 01/2021 - 06/2003
17	COVID-19 11/2022 - 01/2020
17	Virus Diseases (Viral Diseases) 01/2022 - 04/2005
15	Dengue (Dengue Fever) 01/2020 - 03/2012
11	Ebola Hemorrhagic Fever 01/2021 - 01/2016
11	Respiratory Syncytial Virus Infections 03/2015 - 07/2003
9	Severe Dengue 12/2018 - 03/2012
7	Communicable Diseases (Infectious Diseases) 01/2022 - 05/2013
6	Reinfection 01/2022 - 08/2014
6	Smallpox (Variola) 07/2008 - 04/2004
5	Inflammation (Inflammations) 01/2021 - 01/2020
5	Vaccinia 10/2019 - 09/2004
4	Zika Virus Infection 10/2020 - 01/2017
4	Neoplasms (Cancer) 09/2020 - 06/2003
4	Coinfection 01/2016 - 03/2007
3	Weight Loss (Weight Reduction) 05/2020 - 01/2015
3	Convalescence 01/2019 - 04/2004
3	Acquired Immunodeficiency Syndrome (AIDS) 05/2016 - 01/2007
3	Respiratory Tract Infections (Respiratory Tract Infection) 01/2016 - 03/2004
2	Persistent Infection 01/2022 - 02/2016
2	Breakthrough Infections 01/2022 - 07/2021
2	Staphylococcal Infections 11/2021 - 12/2010
2	West Nile Fever 10/2021 - 01/2019
2	Hantavirus Infections 07/2021 - 01/2021
2	Alphavirus Infections 11/2020 - 01/2018
2	Viremia 01/2019 - 06/2017
2	Arthritis (Polyarthritis) 01/2019 - 01/2017
2	Filoviridae Infections 01/2018 - 01/2018
2	HIV Infections (HIV Infection) 01/2016 - 01/2015
2	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2012 - 01/2010
1	Vesicular Stomatitis 01/2022
1	Disease Progression 01/2022
1	Sepsis (Septicemia) 01/2022
1	Adenocarcinoma of Lung 01/2021
1	Lung Diseases (Lung Disease) 12/2020
1	Coronavirus Infections 12/2020
1	Flavivirus Infections 10/2020
1	Marburg Virus Disease 10/2020
1	Immunoglobulin Light-chain Amyloidosis 01/2020
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 01/2020

Drug/Important Bio-Agent (IBA)

58	AntibodiesIBA 11/2022 - 09/2008
55	Monoclonal AntibodiesIBA 03/2022 - 07/2008
45	VaccinesIBA 10/2022 - 06/2003
40	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2005
33	EpitopesIBA 10/2021 - 04/2003
27	Neutralizing AntibodiesIBA 03/2022 - 09/2008
13	Hemagglutinins (Hemagglutinin)IBA 01/2021 - 03/2010
10	Antiviral Agents (Antivirals)IBA 01/2022 - 04/2011
10	Broadly Neutralizing AntibodiesIBA 01/2022 - 07/2010
9	AntigensIBA 01/2022 - 04/2003
9	Immunoglobulin G (IgG)IBA 01/2022 - 06/2003
8	CytokinesIBA 06/2017 - 04/2004
7	RNA (Ribonucleic Acid)IBA 01/2022 - 05/2009
7	Glycoproteins (Glycoprotein)IBA 01/2022 - 07/2015
6	Messenger RNA (mRNA)IBA 12/2021 - 08/2012
6	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019 - 01/2007
5	Neuraminidase (Sialidase)IBA 12/2019 - 10/2012
5	Polysaccharides (Glycans)IBA 01/2019 - 01/2018
4	Peptides (Polypeptides)IBA 10/2020 - 03/2007
4	Dengue VaccinesIBA 01/2019 - 06/2013
4	Blocking AntibodiesIBA 01/2018 - 03/2012
4	Fc Receptors (Fc Receptor)IBA 01/2018 - 03/2012
3	Biological ProductsIBA 01/2022 - 02/2011
3	Ebola VaccinesIBA 01/2021 - 01/2019
3	Complementarity Determining Regions (Complementarity Determining Region)IBA 10/2020 - 12/2009
3	MucinsIBA 01/2019 - 05/2009
2	cilgavimab and tixagevimab drug combinationIBA 01/2022 - 01/2022
2	COV2-2130IBA 05/2020 - 01/2020
2	IronIBA 01/2019 - 12/2010
2	Immune Sera (Antisera)IBA 01/2019 - 10/2014
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019 - 03/2002
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 12/2012
2	Carrier Proteins (Binding Protein)IBA 04/2015 - 12/2010
2	InterferonsIBA 08/2012 - 04/2004
2	Viral RNAIBA 12/2010 - 05/2009
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 12/2010 - 05/2009
2	EnzymesIBA 07/2008 - 03/2007
2	Aventis Pasteur smallpox vaccineIBA 03/2005 - 09/2004
1	ADM03820IBA 03/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022
1	OMPA outer membrane proteinsIBA 01/2022
1	PorinsIBA 01/2022
1	Therapeutic UsesIBA 12/2021
1	Photosensitizing Agents (Photosensitizers)IBA 11/2021
1	Subgenomic RNAIBA 01/2021
1	Angiotensin-Converting Enzyme 2IBA 01/2021
1	atoltivimabIBA 01/2021
1	odesivimabIBA 01/2021
1	Sulfates (Sulfates, Inorganic)IBA 01/2021
1	maftivimabIBA 01/2021
1	ansuvimabIBA 01/2021
1	Cyclic PeptidesIBA 10/2020
1	COV2-2196IBA 01/2020
1	Single-Chain AntibodiesIBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020

Therapy/Procedure

21	Therapeutics 03/2022 - 03/2002
2	Hematopoietic Stem Cell Transplantation 03/2012 - 01/2010